Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
暂无分享,去创建一个
Luca Fabris | Mario Strazzabosco | C. Spirlí | L. Fabris | M. Cadamuro | M. Strazzabosco | Carlo Spirli | S. Brivio | R. Joplin | Massimiliano Cadamuro | Simone Brivio | Ruth E. Joplin | C. Spirli
[1] Yusuke Nakamura,et al. Enhanced Expression of RAD51 Associating Protein-1 Is Involved in the Growth of Intrahepatic Cholangiocarcinoma Cells , 2008, Clinical Cancer Research.
[2] R. Wells,et al. Lineage tracing demonstrates no evidence of cholangiocyte epithelial‐to‐mesenchymal transition in murine models of hepatic fibrosis , 2011, Hepatology.
[3] Sara R. Selitsky,et al. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells , 2015, Nature Communications.
[4] Stefano Piccolo,et al. YAP/TAZ at the Roots of Cancer. , 2016, Cancer cell.
[5] A. Franchitto,et al. Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. , 2006, The American journal of pathology.
[6] Z. Estrov,et al. Leukemia‐inhibitory factor stimulates breast, kidney and prostate cancer cell proliferation by paracrine and autocrine pathways , 1996, International journal of cancer.
[7] Jeong-Seok Nam,et al. Cancer stem cells: the 'Achilles heel' of chemo-resistant tumors. , 2014, Recent patents on anti-cancer drug discovery.
[8] R. Sakai,et al. Direct Interaction between Carcinoma Cells and Cancer Associated Fibroblasts for the Regulation of Cancer Invasion , 2015, Cancers.
[9] C. Spirlí,et al. Pathophysiology of cholangiopathies. , 2005, Journal of clinical gastroenterology.
[10] S. Chien,et al. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis , 2016, Proceedings of the National Academy of Sciences.
[11] G. Gores,et al. The Anti-apoptotic Protein Mcl-1 Inhibits Mitochondrial Ca2+ Signals* , 2005, Journal of Biological Chemistry.
[12] B. Jang,et al. Clinicopathologic Significance of Sox2, CD44 and CD44v6 Expression in Intrahepatic Cholangiocarcinoma , 2014, Pathology & Oncology Research.
[13] R. Tohtong,et al. CD24 induces the invasion of cholangiocarcinoma cells by upregulating CXCR4 and increasing the phosphorylation of ERK1/2 , 2013, Oncology letters.
[14] S. Chaney,et al. Protein interactions with platinum-DNA adducts: from structure to function. , 2004, Journal of inorganic biochemistry.
[15] C. Cordon-Cardo,et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.
[16] C. Desbois-Mouthon,et al. Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor , 2013, Hepatology.
[17] A. Floreani,et al. Epidemiological aspects of biliary tree tumors in a region of northern Italy: emerging trends and sex-based differences , 2013, European journal of gastroenterology & hepatology.
[18] M. Elkind. Epidemiology and Risk Factors , 2011, Continuum.
[19] Michael Fraser,et al. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[20] D. Schuppan,et al. Macrophage recruitment by fibrocystin‐defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis , 2016, Hepatology.
[21] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[22] Zhiwei Wang,et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. , 2010, Biochimica et biophysica acta.
[23] Yangde Zhang,et al. Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells , 2011, Molecular Cancer.
[24] T. Yang,et al. Insights into Chemoresistance of Prostate Cancer , 2015, International journal of biological sciences.
[25] H. Pinedo,et al. Anti‐tumor activity of CPT‐11 in experimental human ovarian cancer and human soft‐tissue sarcoma , 1997, International journal of cancer.
[26] J. Mott,et al. XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells , 2014, PloS one.
[27] W L Allen,et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death , 2006, Oncogene.
[28] Katrin Wlcek,et al. The analysis of organic anion transporting polypeptide (OATP) mRNA and protein patterns in primary and metastatic liver cancer , 2011, Cancer biology & therapy.
[29] A. Diehl,et al. Hedgehog signaling in cholangiocytes , 2011, Current opinion in gastroenterology.
[30] J C Reed,et al. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.
[31] R. Franke,et al. Pharmacogenetics of the organic anion transporting polypeptide 1A2. , 2009, Pharmacogenomics.
[32] K. Shiraki,et al. Cellular FLICE/Caspase-8–Inhibitory Protein as a Principal Regulator of Cell Death and Survival in Human Hepatocellular Carcinoma , 2003, Laboratory Investigation.
[33] R. Qin,et al. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells , 2011, International journal of cancer.
[34] J C Reed,et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. , 1998, Cancer research.
[35] John Calvin Reed,et al. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] G. Gores,et al. GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis , 2010, Oncogene.
[37] G. Carpino,et al. Cholangiocarcinoma: Epidemiology and risk factors , 2011 .
[38] Y. Lo,et al. Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers , 2015, Oncotarget.
[39] M. Vogler. Targeting BCL2-Proteins for the Treatment of Solid Tumours , 2014, Advances in medicine.
[40] H. Thomas,et al. p53 mutations in human cholangiocarcinoma: a review , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[41] S. Fulda. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). , 2014, Advances in experimental medicine and biology.
[42] Makiko Takahashi,et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins , 2010, Breast Cancer Research.
[43] M. Ogawa,et al. Leukemia inhibitory factor induces apoptosis and proliferation of human carcinoma cells through different oncogene pathways , 1997, International journal of cancer.
[44] O. Briz,et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib , 2013, Hepatology.
[45] T. Pawlik,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.
[46] Xin Zeng,et al. Inhibition of Wnt/β‐catenin signaling downregulates P‐glycoprotein and reverses multi‐drug resistance of cholangiocarcinoma , 2013, Cancer science.
[47] D. Goldstein,et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer , 2014, Front. Physiol..
[48] J. Marin,et al. Molecular Bases of Chemoresistance in Cholangiocarcinoma. , 2017, Current drug targets.
[49] L. Fabris,et al. Development of the bile ducts: essentials for the clinical hepatologist. , 2012, Journal of hepatology.
[50] T. Burnouf,et al. Regulation of Tumor Growth and Metastasis: The Role of Tumor Microenvironment , 2014, Cancer growth and metastasis.
[51] Michael Karin,et al. NF-kappaB in cancer: a marked target. , 2003, Seminars in cancer biology.
[52] S. Vickers,et al. Tamoxifen-mediated growth inhibition of human cholangiocarcinoma. , 1997, Cancer research.
[53] G. Gores,et al. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. , 2013, Gastroenterology.
[54] J. Panyam,et al. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[55] W. Tassaneeyakul,et al. Characterization of 5-Fluorouracil-Resistant Cholangiocarcinoma Cell Lines , 2008, Chemotherapy.
[56] C. Pairojkul,et al. Periostin activates integrin α5β1 through a PI3K/AKT‑dependent pathway in invasion of cholangiocarcinoma. , 2012, International journal of oncology.
[57] Tara Karnezis,et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.
[58] Michael Karin,et al. NF-κB in cancer: a marked target , 2003 .
[59] Lei-bo Xu,et al. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro. , 2014, Oncology reports.
[60] C. Heeschen,et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.
[61] A. Arlt,et al. Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.
[62] M. Manns,et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.
[63] G. Gores,et al. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.
[64] P. Heinrich,et al. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. , 1998, The Biochemical journal.
[65] R. Fiorotto,et al. Notch signalling beyond liver development: emerging concepts in liver repair and oncogenesis. , 2013, Clinics and research in hepatology and gastroenterology.
[66] B. Wolpin,et al. A step forward in the treatment of advanced biliary tract cancer. , 2010, The New England journal of medicine.
[67] D. Seehofer,et al. Hedgehog pathway as a potential treatment target in human cholangiocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.
[68] B. Guillotin,et al. The LIF cytokine: towards adulthood. , 2009, European cytokine network.
[69] T. Kisseleva,et al. Is it the end of the line for the EMT? , 2011, Hepatology.
[70] P. Heinrich,et al. Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells , 2005, Journal of Cell Science.
[71] N. Samadi,et al. Tumor microenvironment-mediated chemoresistance in breast cancer. , 2016, Breast.
[72] G. Gores,et al. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. , 2005, Gastroenterology.
[73] M. Aglietta,et al. Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient , 2015, Tumor Biology.
[74] Andrew H. Beck,et al. Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma , 2012, Proceedings of the National Academy of Sciences.
[75] I. Ng,et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.
[76] L. Fabris,et al. Epithelial-mesenchymal interactions in biliary diseases. , 2011, Seminars in liver disease.
[77] J. Marin. Plasma Membrane Transporters in Modern Liver Pharmacology , 2012, Scientifica.
[78] G. Semenza,et al. Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells , 2012, Proceedings of the National Academy of Sciences.
[79] F. Giuliante,et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. , 2015, The American journal of pathology.
[80] A. Bauer,et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors , 2015, Hepatology.
[81] S. Nagata,et al. Fas‐mediated cholangiopathy in the murine model of graft versus host disease , 2000, Hepatology.
[82] Raghu Kalluri,et al. Fibroblasts in cancer , 2006, Nature Reviews Cancer.
[83] Y. Nakanuma,et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease , 2008, Proceedings of the National Academy of Sciences.
[84] K. Watabe,et al. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition , 2013, OncoTargets and therapy.
[85] Yabing Chen,et al. Structural and Biophysical Characterization of the Interactions between the Death Domain of Fas Receptor and Calmodulin* , 2013, The Journal of Biological Chemistry.
[86] T. Patel,et al. Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. , 2006, Journal of hepatology.
[87] T. Utsunomiya,et al. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. , 2011, Hepato-gastroenterology.
[88] R. Qin,et al. Isolation and characterization of tumorigenic extrahepatic cholangiocarcinoma cells with stem cell‐like properties , 2011, International journal of cancer.
[89] G. Gores,et al. Myofibroblast‐derived PDGF‐BB promotes hedgehog survival signaling in cholangiocarcinoma cells , 2011, Hepatology.
[90] G. Gores,et al. Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.
[91] S. Moriyama,et al. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.
[92] Rachelle W Johnson,et al. Leukemia inhibitory factor: A paracrine mediator of bone metabolism , 2012, Growth factors.
[93] A. Franchitto,et al. An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[94] R. Fiorotto,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Protein Kinase A-Dependent pSer-b-catenin, a Novel Signaling Defect in a Mouse Model of Congenital Hepatic Fibrosis , 2013 .
[95] Yinping Tong,et al. Involvement of Wnt/β-catenin signaling in the mesenchymal stem cells promote metastatic growth and chemoresistance of cholangiocarcinoma , 2015, Oncotarget.
[96] K. Kinzler,et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.
[97] K. Torgersen,et al. Human Naturally Occurring and Adaptive Regulatory T cells Secrete High Levels of Leukaemia Inhibitory Factor upon Activation , 2008, Scandinavian journal of immunology.
[98] E. Gaudio,et al. Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[99] R. Fiorotto,et al. Platelet‐derived growth factor‐D and Rho GTPases regulate recruitment of cancer‐associated fibroblasts in cholangiocarcinoma , 2013, Hepatology.
[100] Jorge A. Almenara,et al. Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications. , 2014, Experimental and molecular pathology.
[101] L. Aghajanova. Leukemia Inhibitory Factor and Human Embryo Implantation , 2004, Annals of the New York Academy of Sciences.
[102] Dong-Yan Shen,et al. β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma. , 2015, World journal of gastroenterology.
[103] F. Zouein,et al. LIF and the heart: just another brick in the wall? , 2013, European cytokine network.
[104] P. Dalerba,et al. Identification of pancreatic cancer stem cells. , 2006, Cancer research.
[105] P. Dubus,et al. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution , 2016, Oncotarget.
[106] Tobias Sjöblom,et al. PDGF receptors as cancer drug targets. , 2003, Cancer cell.
[107] LIF-Dependent Signaling: New Pieces in the Lego , 2011, Stem Cell Reviews and Reports.
[108] J. Neuberger,et al. Characterization and isolation of ductular cells coexpressing neural cell adhesion molecule and Bcl-2 from primary cholangiopathies and ductal plate malformations. , 2000, The American journal of pathology.
[109] M. Manns,et al. Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma , 2013, Hepatology.
[110] S. Morrison,et al. Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[111] S. Groshen,et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] M. Selvakumaran,et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. , 2003, Cancer research.
[113] M. Poupon,et al. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts , 2009, British Journal of Cancer.
[114] Yan Liu,et al. Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors. , 2015, European journal of medicinal chemistry.
[115] G. Gores,et al. Polo‐like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma , 2013, Hepatology.
[116] H. Hong,et al. Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. , 2011, Biochemical and biophysical research communications.
[117] M. Daidone,et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer , 2002, Cellular and Molecular Life Sciences CMLS.
[118] Justin L. Mott,et al. miR‐25 targets TNF‐related apoptosis inducing ligand (TRAIL) death receptor‐4 and promotes apoptosis resistance in cholangiocarcinoma , 2012, Hepatology.
[119] Christine Otway. Just another brick in the wall , 2007 .
[120] A. Franchitto,et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. , 2000, Gastroenterology.
[121] L. Fabris,et al. Notch signaling in hepatocellular carcinoma: guilty in association! , 2012, Gastroenterology.
[122] Hans Clevers,et al. Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.
[123] H. Baba,et al. Wnt signaling regulates hepatobiliary repair following cholestatic liver injury in mice , 2016, Hepatology.
[124] T. Takayama,et al. Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-π-Specific Inhibitor O1-Hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester , 2003, Journal of Pharmacology and Experimental Therapeutics.
[125] T. Wang,et al. Identification of Gastric Cancer Stem Cells Using the Cell Surface Marker CD44 , 2009, Stem cells.
[126] W. El-Deiry,et al. Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[127] C. Tiribelli,et al. The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study , 2013, PloS one.
[128] G. Gores,et al. Inhibition of interleukin 6–mediated mitogen‐activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line , 1999, Hepatology.
[129] G. Gores. Cholangiocarcinoma: Current concepts and insights , 2003, Hepatology.
[130] I. Hwang,et al. Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients , 2011, Cancer Chemotherapy and Pharmacology.
[131] Thomas Kirchner,et al. Migrating cancer stem cells — an integrated concept of malignant tumour progression , 2005, Nature Reviews Cancer.
[132] G. Wong,et al. Hyaluronan-CD44v3 Interaction with Oct4-Sox2-Nanog Promotes miR-302 Expression Leading to Self-renewal, Clonal Formation, and Cisplatin Resistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma* , 2012, The Journal of Biological Chemistry.
[133] S. Orsulic,et al. Ovarian Cancer , 1993, British Journal of Cancer.
[134] W. Hung,et al. Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. , 2013, Oncology reports.
[135] S. Fan,et al. Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.
[136] S. Dupont,et al. The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.
[137] R. Jesenofsky,et al. Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.
[138] Hongxiang Liu,et al. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma , 2011, BMC Cancer.
[139] M. Serrano,et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. , 2012, Molecular pharmaceutics.
[140] G. Gores,et al. Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.
[141] R. Hynes,et al. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.
[142] A. Floreani,et al. Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation , 2015, Oncotarget.
[143] T. Utsunomiya,et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma , 2010, Journal of Gastroenterology.
[144] K. Boberg,et al. Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) , 2016, Nature Reviews Gastroenterology &Hepatology.
[145] James B. Mitchell,et al. Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF‐κB , 2000, Head & neck.
[146] S. Hector,et al. In vitro studies on the mechanisms of oxaliplatin resistance , 2001, Cancer Chemotherapy and Pharmacology.
[147] Li Xing. Advances in pathogenesis,diagnosis and treatment strategies of food allergy , 2014 .
[148] L. Fabris,et al. Unveiling the role of tumor reactive stroma in cholangiocarcinoma: an opportunity for new therapeutic strategies. , 2013, Translational gastrointestinal cancer.
[149] S. Dupont,et al. Molecular Pathways Molecular Pathways : YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis , 2013 .
[150] R. Rousseau,et al. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. , 2011, Anticancer research.
[151] M. Alison. Liver stem cells , 2007, Stem Cell Reviews.
[152] N. Khuntikeo,et al. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. , 2012, World journal of gastroenterology.
[153] Giuseppe Basso,et al. YAP/TAZ Incorporation in the β-Catenin Destruction Complex Orchestrates the Wnt Response , 2014, Cell.
[154] H. Van Vlierberghe,et al. Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. , 2016, Journal of hepatology.
[155] G. Gores,et al. Bcl‐2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line , 1997, Hepatology.
[156] Ricardo J. Ferreira,et al. P-glycoprotein and membrane roles in multidrug resistance. , 2015, Future medicinal chemistry.
[157] P. Johnston,et al. Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan , 2004, Clinical Cancer Research.
[158] G. Chalkiadakis,et al. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients? , 2001, The Journal of surgical research.
[159] Shufeng Zhou,et al. Molecular mechanisms for tumour resistance to chemotherapy , 2016, Clinical and experimental pharmacology & physiology.
[160] P. Heinrich,et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.
[161] H. Dvorak. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.
[162] A. Paradiso,et al. Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer , 2001, British Journal of Cancer.
[163] J. Llovet,et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. , 2012, Gastroenterology.
[164] C. Heldin,et al. Mechanism of action and in vivo role of platelet-derived growth factor. , 1999, Physiological reviews.
[165] F. Dufour,et al. Death receptors as targets in cancer , 2013, British journal of pharmacology.
[166] Kaiming Wu,et al. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. , 2016, Gene.
[167] J. Pollard,et al. Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.
[168] R. Pochampally,et al. Human multipotent stromal cells from bone marrow and microRNA: Regulation of differentiation and leukemia inhibitory factor expression , 2008, Proceedings of the National Academy of Sciences.
[169] G. Gores,et al. Classification, diagnosis, and management of cholangiocarcinoma. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[170] Bill Bynum,et al. Lancet , 2015, The Lancet.
[171] K. Mimori,et al. CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.
[172] R. Edwards,et al. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer , 2013, Disease Models & Mechanisms.
[173] J. Becker,et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. , 2009, Cancer research.
[174] H. Gascan,et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. , 2007, Blood.
[175] Johanna Andrae,et al. Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.
[176] A. Sica,et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. , 2017, Journal of hepatology.
[177] R. Tohtong,et al. Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. , 2011, International journal of oncology.
[178] S. Aebi,et al. The role of DNA mismatch repair in drug resistance. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[179] M. Strazzabosco,et al. Emerging roles of Notch signaling in liver disease , 2015, Hepatology.
[180] A. Sabichi,et al. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. , 2013, Blood.
[181] H. Baba,et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma , 2010, Cancer science.